计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| P187973-250mg |
250mg |
现货 ![]() |
| |
| P187973-1g |
1g |
现货 ![]() |
| |
| P187973-5g |
5g |
期货 ![]() |
|
| 别名 | N-(6-甲氧基喹啉-8-基)戊-1,4-二胺 |
|---|---|
| 英文别名 | BPBio1_000674 | SN 13,272 | (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine | Kanaprim | N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine | 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline | dl-Primaquine | NCGC00178754-02 | Prestwick3_000476 | BSPBio |
| 规格或纯度 | Moligand™, ≥95% |
| 英文名称 | Primaquine |
| 储存温度 | 2-8°C储存 |
| 运输条件 | 冰袋运输 |
| 纯度 | ≥95% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504750829 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine |
| INCHI | 1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3 |
| InChi Key | INDBQLZJXZLFIT-UHFFFAOYSA-N |
| Smiles | CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2 |
| Isomeric SMILES | CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2 |
| PubChem CID | 4908 |
| 分子量 | 259.4 |
| 分子量 | 259.350 g/mol |
|---|---|
| XLogP3 | 2.200 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 259.168 Da |
| 单同位素质量Monoisotopic Mass | 259.168 Da |
| 拓扑极表面积Topological Polar Surface Area | 60.200 Ų |
| 重原子数Heavy Atom Count | 19 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 262.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 1 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 |
|---|
| 1. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. (2006) Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.. Am J Trop Med Hyg, 75 (3): (402-15). [PMID:16968913] |
| 2. Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, Sattabongkot J, Jambert E, Domingo GJ, Commons R et al.. (2017) Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group.. Malar J, 16 (1): (141). [PMID:28381261] |